Background: In Belgium, new and costly antiepileptic drugs (AEDs) are only reimbursed as second-line treatment, after documented treatment with conventional and cheaper AEDs has failed. The objective of this study was to describe the treatment of epilepsy in Belgium and to analyze the impact of the reimbursement restrictions on the choice of AEDs. Methods: Between May and June 2003, a sample of 100 neurologists, representative of the entire neurological community in teaching, academic, and regional hospitals in Belgium, were personally interviewed on the basis of a structured questionnaire (modified Rand method). The questionnaire contained questions on treatment choices and strategies in adult epilepsy. Results: Unanimously, initial monotherapy was the preferred treatment strategy in all types of epilepsy. In the opinion of most neurologists, valproate was the first choice for idiopathic generalized and focal epilepsy with/without secondary generalization. Carbamazepine as their first choice for the treatment of focal epilepsy. New AEDs were most often prescribed as second-line therapy. Lamotrigine was the most frequently prescribed new AED and used for both generalized and focal epilepsy. It was followed by levetiracetam, topiramate and oxcarbazepine for focal epilepsy. In
Introduction
Epilepsy is one of the most common chronic neurologic disorders, affecting about 1 in 200 people. 1 About 70,000 individuals in Belgium are affected by seizures. Many patients have substantial disability and severe physical, neuropsychological, and behavioural complications. The economic consequences of epilepsy are enormous considering the use of health care resources and loss of productivity. [2] [3] [4] [5] [6] Current treatment of epilepsy includes a variety of older and newer antiepileptic drugs (AEDs). Until the early 1990s, the most important AEDs were carbamazepine, ethosuximide (for absence seizures), phenobarbital, phenytoin, primidone, and valproate. Using these compounds, about 50% of patients with newly diagnosed epilepsy achieved seizure control immediately after initiation of therapy, and 20-30% achieved remission after one or more adaptations of the dosage or after switch to another AED. 7 About 20-30% of patients ''failed'' all available options, either because their seizures were not adequately controlled, or they were experiencing adverse effects. 8 In addition, they have complex pharmacokinetics (e.g., hepatic enzyme inducers or inhibitors) and are therefore prone to drug-drug interactions.
New AEDs, such as felbamate, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, pregabalin, tiagabine, topiramate, and vigabatrin have been added to the therapeutic armamentarium, but the costs are substantially higher compared to the conventional drugs. 9 For many patients, the new AEDs may reduce or eliminate seizures with fewer side effects, depending to their gender, age, type of epilepsy or other factors.
New AEDs are usually investigated as add-on regimens to standard therapy in randomized clinical trials, and therefore after launch labelled as second-line therapy, if conventional therapy has failed. In terms of reimbursement in several countries, including Belgium, where treatment is free or heavily subsidized to the patient at the point of delivery, a similar approach is taken: the newer drugs are only covered if documented treatment with conventional and cheaper AEDs has failed. This approach is often maintained even if high-quality studies on efficacy and safety of new AEDs in firstline treatment have become available. 10 The impact of the reimbursement restrictions on the treatment of epilepsy in Belgium has not been systematically investigated. Principally, a suitable approach encompasses drug utilization data which can be derived from the insurance companies. For example, the differences in treatment patterns between schemes with unrestricted reimbursement versus restricted reimbursement can be compared. However, data on diagnoses are often not robust, which makes it difficult to draw conclusions.
Thus, we conducted a survey among a representative panel of Belgian expert neurologists throughout the country in order to examine overall treatment strategies and the impact of reimbursement restrictions.
Methods Design
A newly developed expert opinion model derived from the Rand method was used, which aims to minimize the interaction between survey participants. 11, 12 We used a quantitative analysis of responses to a personal interview to determine where opinions converge and to summarize the resulting opinion. 13 The process has been used in a comprehensive survey on the same topic in the US, which served as a template, with certain modifications, for our survey. 14 
Sample
The selection of the sample was based upon the following rules: (1) 100% of all teaching hospitals were to be represented by two neurologists each; (2) 50% of all peripheral hospitals were to be represented by one clinician each. Of a nationwide sample of n = 511 eligible neurologists in these hospitals, a total of n = 100 were drawn randomly. In the group of questions about generalized and FE, besides the overall treatment strategy, the initial therapy (a) with reimbursement restrictions (''real world'') and (b) without reimbursement restrictions (''ideal world'') was investigated. Two main types of questions were asked. First, after having been briefed with short case vignettes, physicians were asked to describe their treatment strategy in seven to eight steps. The strategy at each step was to be decided upon the assumption that there was no response to therapy during the preceding step. For this type of question, only a general approach was asked for (i.e., AED monotherapy, add-on therapy, switch; non-pharmacological approaches). The other main type of question focussed on the use of specific AEDs. Here, after having been given the case vignette, a list of 16 drugs and two to three non-drug measures (presurgical evaluation; vagus nerve stimulation, ketogenic diet) was provided. Physicians were asked to rate each drug or measure according to a 5-point scale (1. treatment you would prescribe as firstline; 2. treatment you would prescribe as secondline; 3. treatment you would prescribe as third-line; 4 treatment you would never prescribe. 5. No opinion/ unknown drug). For therapies rated with 1 or 2, neurologists were asked to indicate the predominant reason for the response (a: evidence in the medical literature, b: experience, c: experience/opinion of colleagues, d: other).
The questionnaire was tested in a pilot stage with 16 neurologists from teaching hospitals (n = 12) and peripheral hospitals (n = 4). At this stage, assessments were made concerning the intelligibility of items, completeness of questionnaires, and feedback provided by neurologists.
Statistics
As the basic scale was ordinal (i.e., not quantitative), only specific descriptive statistics were calculated and non-parametric tests performed: the percentages of neurologists considering the various AED treatments as first-, second-, or third-line (including the confidence intervals of proportions of neurologists considering the treatments as first-, second-, or third-line). The presence or absence of consensus was defined as a distribution likely or unlikely to occur by chance by performing a Kolmogorov-Smirnov D test of the distribution of scores across the four ranges of appropriateness. Other comparisons were done with the Z test. Significance was determined at the a= 0.05 level with correction for the finite population.
Reimbursement criteria
The reimbursement criteria in Belgium at the time of the survey were as follows: ''old'' AED (carbamazepine, ethosuximide, phenobarbital, phenytoin, primidone, valproate) were reimbursed as first-line treatment. Lamotrigine and oxcarbazepine were reimbursed in monotherapy only after failure or adverse effects (tolerability issues) of ''old'' drugs, and as add-on therapy to ''old'' drugs. The ''new'' drugs levetiracetam, tiagabine, topiramate, and vigabatrin were reimbursed as add-on therapy for FE only. Felbamate was reimbursed as add-on in Lennox-Gastaut syndrome only.
Results
Of all invited neurologists, the final sample consisted of six academic neurologists and 94 neurologists in other hospitals. On average, physicians saw 24.5 (AE17.0) patients with epilepsy per month.
General treatment strategy
For both IGE and FE, general treatment strategies were very uniform: almost all experts would start with monotherapy (100% in IGE, 98% in FE). In case of failure, 74% (IGE) or 66% (FE) would switch to another monotherapy, and 26% (IGE) or 31% (FE) would use two drugs. As for a third step, heterogeneity in recommendations increased. For example in IGE, experts recommended after monotherapy in steps 1 and 2 another monotherapy in step 3 in 15% and dual combination therapy in 59%. In FE, they recommended after monotherapy in steps 1 and 2 a switch to another monotherapy in step 3 in 15%, and dual combination therapy in 52%. Fig. 1 displays the overall treatment schemes in IGE (top) and FE (bottom), summarizing expert treatment decisions.
Idiopathic generalized epilepsy Fig. 2 (top) lists the AED treatment options according to the expert ranking in the indication IGE/tonicclonic seizures in real life, i.e., with reimbursement restrictions. The first-line shows that 98% of experts would use VPA as first-line therapy, 1% as second-line therapy, and 0% as third-line therapy in this condition (1% ''never''). Lamotrigine was chosen by 17% as first-line, by 64% as second-line and by 14% as third-line therapy, making it the most preferred second-line drug. Three drugs (topiramate, levetiracetam, and phenytoin) were preferred as third-line drugs. According to significance testing, the level of consensus was high. Only in the case of carbamazepine was there no consensus. Fig. 2 (bottom) displays the experts' answers to the same case, however, assuming there were no reimbursement restrictions in Belgium. The AED order remained basically the same, and there were no major differences in the ''old'' drugs (valproate, phenytoin) nor in those drugs, which would be ''never'' used in this indication. There were important differences for lamotrigine. Without restrictions, it would be used much more frequently as first-line (33% versus 17%, p = sign.) instead of second-line (49% versus 65% with restrictions, p = sign.). Similar effects, albeit of smaller size, could be observed for topiramate and levetiracetam. There was consensus among experts for all AEDs with the exception of carbamazepine.
For absence seizures, VPA was the only drug considered as first choice by the majority of experts (1st: 93%, 2nd: 1%, 3rd: 0%, never: 6%). Lamotrigine was most frequently cited as second choice (1st: 12%, 2nd: 53%, 3rd: 17%, never: 18%). All other drugs were most frequently ''never'' used, and there was consensus on the statistical test with exception of ethosuximide (rank 3 with 1st: 21%, 2nd: 30%, 3rd: 13%, never: 36%). Importantly, there were no significant differences in this indication with and without reimbursement restrictions.
For IGE with myoclonic seizures, VPA was the only drug considered as 1st choice by the majority of experts (1st: 91%, 2nd, 4%, 3rd: 0%, never: 5%), while lamotrigine (1st: 13%, 2nd: 53%, 3rd: 18%, never: 16%), and levetiracetam (1st: 4%, 2nd: 39%, 3rd: 22%, never: 35%) were most frequently rated as second choice. All other drugs were most frequently categorized as ''never'' used. There were no significant differences with and without reimbursement restrictions. Fig. 3 lists the AED treatment options according to the expert ranking for focal seizures. Carbamazepine was the only AED considered as first choice by the majority of experts (1st: 91%, 2nd: 5%, 3rd: 1%, never: 3%). Lamotrigine, valproate, levetiracetam, topiramate and oxcarbazepine were considered as second choice by the majority, gabapentin and phenytoin as third choice. The other AEDs were predominantly rated in the ''never used'' category. There was consensus for all AEDs.
Focal epilepsy
Impact of reimbursement restrictions on the choice of antiepileptic drugs 353 Figure 1 Overall treatment strategies in the treatment of idiopathic generalized epilepsy and focal epilepsy (bottom). (a) Case description: Healthy adolescent with IGE, no previous therapy, willing to accept all therapies, compliant, each therapy is incremented to toxicity before proceeding to the next step. (b) Case description: Healthy adolescent with FE (for example temporal lobe epilepsy, due to mesial temporal sclerosis, willing to accept all therapies, compliant, each therapy is incremented to toxicity before proceeding to the next steps).
In the absence of reimbursement restrictions, oxcarbazepine would be increasingly used and would be one of the preferred first-line drugs (1st: 55% versus 33% with restrictions, p = sign.; 2nd: 27% versus 45%, p = sign.). The changes for the other AEDs did not achieve significance. Notably, there was no expert consensus about levetiracetam in the absence of reimbursement restrictions.
For FE/ secondarily generalized seizures, carbamazepine (1st: 84%, 2nd: 8%, 3rd: 3%, never: 5%) and valproate (1st: 47%, 2nd: 33%, 3rd: 12%, never: 8%) were considered as first choice by the majority of experts (Fig. 4) . Lamotrigine, topiramate, levetiracetam and oxcarbazepine were rated as second choice, gabapentin and phenytoin as third choice; the other drugs were predominantly ''never'' used. There was consensus for all AEDs.
In the absence of reimbursement restrictionsas in focal seizures -oxcarbazepine would be significantly more used and would be one of the preferred first-line drugs (1st: 56% versus 33% with restrictions, p = sign.). The changes in prescription behaviour (with and without reimbursement constraints) for the other AEDs did not achieve significance.
Discussion
The results of this survey may be of major interest for practicing neurologists, but also for health-care providers. In the treatment of epilepsy, a broad armamentarium of drug treatment options exists; however, there are only few randomized controlled trials which compare drugs head-to-head. New drugs are usually investigated as add-on (i.e., second-or third-line) therapy in patients not responding adequately to first-line therapy or not tolerating the first drug. Many typical situations in everyday care of patients with epilepsy are not reflected in 354 P. Boon et al. studies used for regulatory purposes. Consequently, these situations cannot be found in guidelines that are usually based upon the results of randomized controlled clinical trials. In this situation, the recommendations from neurologists in the field who have broad experience can be a valuable source for guidance. In addition, a survey, such as the present one can shed light on the extent to which prescribing behaviour is dependent on external factors, such as reimbursements restrictions.
The key results of our study can be summarized as follows: (1) initial monotherapy is the preferred treatment strategy in both IGE and FE. This finding is in line with the major guidelines. 8, 15 (2) Almost all neurologists considered valproate as first-line therapy for IGE and FE. Carbamazepine was considered first-line for FE. These findings are in line with the results of randomized controlled trials and therefore ''evidence-based''. 16, 17 (3) Reimbursement restrictions had a major impact on the use of lamotrigine, which would be considerably more often be prescribed for IGE, and oxcarbazepine for FE.
Formulary limits on the availability of AEDs are an increasing trend. In order to reduce costs, healthcare institutions, and federal entities are structuring reimbursement constraints favouring the older, less expensive AEDs and restricting or denying access to the new, more expensive ones. The ''fail first'' policies instituted by insurance plans (making proof of failure of an older AED the price of access to a newer) translate into the fact that individuals have to have a seizure or to develop intolerable adverse effects. This is not in keeping with best practice based on existing evidence, as the recent American Academy of Neurology (AAN)/American Epilepsy Society (AES) guidelines point out. After having reviewed evidence from 1462 articles on human clinical studies of new AEDs in epilepsy (the best documented were treatments with lamotrigine [433 articles], topiramate [244 articles] and gabapentin [240 articles]), the AAN/AES compared the ''new'' to the ''old'' AEDs. Both new and old drugs were equally effective in new onset epilepsy, and the newer drugs tended to have fewer adverse effects. 8 All of the new AEDs were found to be appropriate for adjunctive treatment of refractory partial seizures in adults, with limited evidence that lamotrigine and topiramate are also effective for adjunctive treatment of IGE in adults and children, as well as treatment of the Lennox-Gastaut syndrome. 18 Hence, from a scientific Impact of reimbursement restrictions on the choice of antiepileptic drugs 355 viewpoint, the existing reimbursement restrictions in Belgium are problematic. When interpreting the results of the present survey, the strengths and weaknesses of our approach have to be taken into consideration. The expert consensus method that we used analyses pooled opinion statistically and minimizes bias inherent to other approaches. Typical expert ''round tables'' usually reflect the opinion of a small number of participants. Expert members of a consensus conference are influenced by the process of having participated in such a conference 19 and even larger meetings are possibly biased by the influence of strong personalities steering the discussion and recommendations. 13 The ''Rand method'' uses a decentralized approach, which avoids such bias by minimizing interaction between participants. It also is capable of displaying heterogeneity of consensus in certain clinical situations, which often reflects clinical reality to a greater extent than in guidelines derived from clinical studies. No guidelines can address all complexities involved in the care of each individual patient. Sound clinical judgment based on experience is still required in applying these recommendations. The modified Rand method has been used in various indications in psychiatry (bipolar disorder 20 , behavioural emergencies, 21 depression in women, 22 antipsychotics in the elderly 23 ). Among the limitations of our approach, the most important one is that the opinions of experts can be wrong. 14 In terms of evidence, the Cochrane Collaboration assigns the lowest level to the expert opinion, 24 and health technology assessment or guideline development takes a similar approach. 25 However, in our survey, expert opinion matched the recommendations from guidelines closely. Opinion can be subject to change over time, and the survey data represent a snapshot at the time when the survey was made. In this respect, our study shares the problem with clinical trials that reflect treatment standards (i.e., background therapies or treatment strategies) which may be outdated after some years.
A better understanding of the economic aspects should lead to further improvements in epilepsy care by targeting limited resources in the most beneficial way for the patients. 26 Our study shows that reimbursement restrictions have a major impact on daily practice and might be a barrier to optimal treatment. 
